

## Workshop on Development of Long-Acting Treatments for Persons with Hepatitis B

Tuesday, March 18<sup>th</sup>, 2025

*The Westin, Los Angeles, California*

### AGENDA

<b>7:00 – 7:30 AM (PST)</b>	<b>Onsite Registration and Breakfast</b>	
<b>7:30-7:35 AM</b>	<b>Welcome:</b>	<b>David Thomas, Johns Hopkins University</b>
<b>7:35-8:45 AM</b>	<b>Session 1: Public Health and Medical Imperative for Long-Acting HBV Treatments</b>	<b>Norah Terrault, Chair</b>
<b>7:35-7:45 AM</b>	Global Public Health Significance	<b>Funmi Lesi, WHO HQ</b>
<b>7:45-7:55 AM</b>	Target Product Profile – Perspective of Persons Living with Hepatitis B	<b>Chari Cohen, Hepatitis B Foundation</b>
<b>7:55-8:05 AM</b>	Target Product Profile – Medical Perspective	<b>Jordan Feld, TGHRI</b>
<b>8:05-8:15 AM</b>	Market Forecast	<b>Paul Domanico, CHAI</b>
<b>8:15-8:45 AM</b>	Discussion	<b>ALL</b>
<b>8:45-10:10 AM</b>	<b>Session 2: Existing Preclinical Work</b>	<b>Andrew Owen, Chair</b>
<b>8:45-8:55 AM</b>	ETV Prodrug	<b>Anil Gupta, Calibr-Skaggs IIM at Scripps Research</b>
<b>8:55-9:05 AM</b>	ETV	<b>Frederic Dargela, DelsiTech</b>
<b>9:05-9:15 AM</b>	TAF and Other Implants	<b>Marc Baum, Oak Crest Institute of Science</b>
<b>9:15-9:25 AM</b>	TVF Prodrugs	<b>Benson Edagwa, University of Nebraska Medical Center</b>
<b>9:25-9:35 AM</b>	TFV-Based Treatments	<b>Rodney Ho, University of Washington</b>
<b>9:35-10:10 AM</b>	Discussion: What is Needed to Move to the Next Step?	<b>ALL</b>
<b>  10 Minute Break  </b>		

<b>10:20-11:25 AM</b>	<b>Session 3: Overcoming Roadblocks to Development</b>	<b>Veronica Miller, Chair</b>
<b>10:20-10:30 AM</b>	Regulatory Pathways and Issues	<b>Poonum Mishra, FDA</b>
<b>10:30-10:40 AM</b>	Low- and Middle-Income Access	<b>Lobna Gaayeb, MPP</b>
<b>10:40-10:50 AM</b>	Lessons from HIV Drug Development	<b>Charles Flexner, Johns Hopkins University</b>
<b>10:50-11:25 AM</b>	Discussion	<b>ALL</b>
<b>11:25-12:20 PM</b>	<b>Session 4: Industry and Investor Perspective Panel</b>	<b>Mark Sulkowski, Chair</b>
<b>11:25-12:20 PM</b>	What Makes Long-Acting HBV Drug Development Attractive?	<b>Robert Gish, Robert G. Gish Consultants LLC Additional Members TBD</b>
<b>12:20-12:30 PM</b>	<b>Summary and Adjournment</b>	
	Workshop Summary and Next Steps	<b>ALL</b>
	Final Discussion and Adjournment	<b>David Thomas</b>
<b>  Close of Workshop  </b>		

Workshop Sponsors:

US NIH R24AI118397 LEAP (<https://www.longactinghiv.org>) and the GHS (<https://global-hepatitis.com>)